A formulation can successfully carry an ingredient without demonstrating that it delivers an effective amount to the intended tissue. This study addressed carrier properties and laboratory enzyme activity. Primary study
What the researchers measured
Anionic and cationic lecithin-based liposomes were investigated as GHK-Cu carriers. The study characterized size, stability, bilayer fluidity, and encapsulation efficiency. It also tested tyrosinase and elastase inhibition in vitro. GHK-Cu did not significantly affect tyrosinase activity in the reported assay, while elastase inhibition was observed. Primary report
Our appraisal: loading, delivery, and effect are separate stages
Encapsulation efficiency describes how much material is associated with the carrier under a defined measurement method. It does not directly establish release at the skin surface, passage through the barrier, or uptake by target cells. Each step can change the amount and chemical form available.
Carrier stability is also conditional. A stable dispersion during the tested period does not automatically establish a finished product's shelf life across storage conditions or compatibility with other ingredients. The exact formulation and measurement window matter.
An enzyme assay can identify activity under controlled conditions. It cannot by itself demonstrate reduced elastin loss in living skin or visible improvement in appearance. Substrate conditions, assay interference, and suitable controls should be considered before translating inhibition into a tissue-level claim.
The neutral tyrosinase result is part of the evidence. A broad statement that the formulation inhibits all aging- or pigmentation-related enzymes would misrepresent the reported pattern.
This paper provides formulation-development information and a biochemical signal. It does not establish superior clinical delivery, wrinkle reduction, or pigmentation treatment. Full review should inspect loading measurements, separation of free and encapsulated material, stability duration, assay controls, and subsequent permeation evidence. A liposomal label alone is not proof that a commercial product reproduces the investigated system.
Frequently asked questions
Were differently charged carriers investigated?
Yes.
Is encapsulation efficiency the same as skin bioavailability?
No.
Was elastase inhibition observed in vitro?
Yes.
Was a significant tyrosinase effect demonstrated?
No.
Does an enzyme assay directly measure wrinkle reduction?
No.
Does short-term formulation stability establish universal shelf life?
No.
What evidence would connect loading to efficacy?
Validated release, tissue delivery, target effects, and relevant clinical outcomes.